Metformin Shows Promise for Protecting Memory in Early Cognitive Decline

Columbia University conducted a groundbreaking phase II clinical trial investigating whether metformin, a widely-used diabetes medication, could slow cognitive decline in people with amnestic mild cognitive impairment (AMCI). The study was motivated by growing evidence that high insulin levels and type 2 diabetes significantly increase Alzheimer's disease risk, affecting two-thirds of US adults.

The randomized, double-blind, placebo-controlled trial enrolled 80 overweight participants aged 55-90 with AMCI, a transitional state between normal cognition and Alzheimer's disease. Half received metformin while the other half received placebo over approximately four years. The intervention targeted peripheral hyperinsulinemia, which researchers hypothesized impairs the brain's ability to clear amyloid beta plaques.

Researchers measured cognitive performance using standardized memory tests including the Selective Reminding Test and the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog). Additionally, 40 participants underwent PET brain scans to assess functional changes in brain regions typically affected by Alzheimer's disease.

This trial represents a paradigm shift in dementia prevention, targeting metabolic dysfunction rather than brain pathology directly. The approach is particularly relevant given metformin's excellent safety profile and widespread availability. While specific results weren't detailed in the summary, the completed status suggests valuable data on whether metabolic interventions can meaningfully impact cognitive trajectories.

The implications extend beyond cognitive health, as metformin's effects on insulin sensitivity, inflammation, and cellular aging processes may offer broader longevity benefits. This research could inform preventive strategies for the millions of adults at risk for both metabolic dysfunction and cognitive decline.